Price
CHART BY
Frequently asked questions
What is Rigel Pharms's market capitalization?
The market capitalization of Rigel Pharms is $880.57M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Rigel Pharms's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Rigel Pharms is 2.89. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Rigel Pharms?
Rigel Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $16.32. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Rigel Pharms's stock?
Currently, 5 analysts cover Rigel Pharms's stock, with a consensus target price of $63.00. Analyst ratings provide insights into the stock's expected performance.
What is Rigel Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, Rigel Pharms reported a revenue of $276.79M.
What is the EBITDA for Rigel Pharms?
Rigel Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $89.70M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Rigel Pharms?
Rigel Pharms has a free cash flow of $79.39M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Rigel Pharms have, and what sector and industry does it belong to?
Rigel Pharms employs approximately 174 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Rigel Pharms's shares?
The free float of Rigel Pharms is 18.06M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $880.57M
- EPS (TTM)
- $16.32
- Free Float
- 18.06M
- P/E ratio (TTM)
- 2.89
- Revenue (TTM)
- $276.79M
- EBITDA (TTM)
- $89.70M
- Free Cashflow (TTM)
- $79.39M
Pricing
- 1D span
- $46.44$47.86
- 52W span
- $25.00$51.96
Analyst Ratings
The price target is $63.00 and the stock is covered by 5 analysts.
Buy
3
Hold
2
Sell
0
Information
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
- Employees
- 174
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- RIGL
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet